FDA Warns Against Infection Risk From Ophthalmic Drugs Following Meningitis Outbreak
As the investigation into the meningitis outbreak continues, the FDA is recommending that any patients who received injectable drugs purchased from or compounded at the New England Compounding Center after May 21, 2012, be notified of the potential risk of infection, according to an ASCA report.
This includes ophthalmic drugs injected or used in conjunction with eye surgery and cardioplegic solutions. Patients should contact their healthcare provider if they experience symptoms of meningitis.
At this time, no cases of infection have been reported in connection with any NECC-produced ophthalmic drug, but the FDA believes the class of products could present similar infection risks.
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- 15 Statistics on Accounts & Cases in Orthopedic-Driven ASCs
- 6 Proposed Legislative Changes Impacting Surgery Centers & Clinics
- Surgery Center of Fairfield County Opens in New Connecticut Location
- PENTAX Medical, Hitachi-Aloka Medical Continue Partnership to Pursue Endoscopic Ultrasound Systems Development
- 8 Recent GI-Driven Centers & Expansions